Current Investigations

Matrixx | Company Ticker: MTXX

Hagens Berman Sobol Shapiro is investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam products, over the company's reported failure to provide the Food and Drug Administration (FDA) with more than 800 reports relating to the loss of sense of smell associated with the Zicam Cold Remedy intranasal products.

In a letter to Matrixx dated June 16, 2007, the FDA informed Matrixx it concluded that certain Zicam products may pose serious risks to consumers who use them, and that Matrixx marketing practices violate several laws relating to the products.

Upon release of this letter by the FDA, Matrixx stock plummeted from approximately $19 per share to less than $7 per share.

Since December 2007, insiders, including the Executive VP and CFO, the VP of Sales and the VP of Research and Development, have sold more than $2.7 million worth of Matrixx shares.

If you are aware of any facts relating to this investigation, or purchased shares of Matrixx since December 2007, you can assist this investigation by contacting one of our attorneys at Matrixx@hbsslaw.com or joining this investigation.

If you have information about this investigation
please click here.

If you are impacted by this action
please contact us.